Baseline characteristics of 36 mepolizumab-patients. Experiences from the clinical practice

被引：1
|
作者：
Bjerrum, Anne Sofie
Skjold, Tina
Schmidt, Johannes
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2017年 / 50卷
关键词：
D O I：
10.1183/1393003.congress-2017.PA3588
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA3588
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The impact of baseline characteristics differences in patients treated in clinical practice with sacubitril/valsartan versus PARADIGM-HF
    Martens, P. Pieter
    Belien, H.
    Dupont, M.
    Mullens, W.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 73 - 74
  • [22] Disease Severity and Baseline Characteristics of Patients Receiving Mepolizumab or Omalizumab in Employer Claims Database: A real-world experience
    Hahn, Beth
    Llanos-Ackert, Jean-Pierre
    Ortega, Hector
    Packnett, Elizabeth
    Irwin, Debra
    Riehle, Ellen
    Chebili, Christina
    Bell, Christopher
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (02) : AB10 - AB10
  • [23] Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials
    Catherine Lemiere
    Camille Taillé
    Jason Kihyuk Lee
    Steven G. Smith
    Stephen Mallett
    Frank C. Albers
    Eric S. Bradford
    Steven W. Yancey
    Mark C. Liu
    Respiratory Research, 22
  • [24] Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials
    Liu, Mark
    Taille, Camille
    Lee, Jason
    Smith, Steven
    Mallett, Steve
    Martin, Neil
    Howarth, Peter
    Yancey, Steven
    Lemiere, Catherine
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB56 - AB56
  • [25] BASELINE CLINICAL-EPIDEMIOLOGICAL CHARACTERISTICS OF THE PATIENTS IN THE COHORT IMMEX
    Badajoz, Aida Martinez
    Rojas, Francisco Martin Bravo
    Torres, Mario Cesar Ocampo
    Perez, Astrid Asminda Ramirez
    Zaragoza, Miguel Angel Vazquez
    Hernandez, Rocio Catana
    Rivera, Juan Carlos H. Hernandez
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2023, 29 : S48 - S48
  • [26] Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two phase III trials
    Liu, M. C.
    Taille, C.
    Lee, J. K.
    Smith, S. G.
    Mallett, S.
    Martin, N.
    Howarth, P.
    Yancey, S.
    Lemiere, C.
    ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (01) : 87 - 88
  • [27] Patients with severe eosinophilic asthma treated with mepolizumab: A 12-month follow-up from our clinical practice
    Hernandez-Martin, I
    Barranco, P.
    Sanchez-Jareno, M.
    Palao-Ocharan, P.
    Dominguez-Ortega, J.
    Romero-Ribate, D.
    Luna-Porta, J. A.
    Quirce, S.
    ALLERGY, 2019, 74 : 713 - 713
  • [28] Baseline Characteristics and Outcomes in Patients with Anemia in Clinical Studies of Tofacitinib
    Moeller, Burkhard
    Finckh, Axel
    Alvaro-Gracia, Jose Maria
    Scholz, Godehard
    Aletaha, Daniel
    Biondo, Francesca
    Strengholt, Sander
    Rivas, Jose L.
    Connell, Carol A.
    Shi, Harry
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [29] Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials
    Lemiere, Catherine
    Taille, Camille
    Lee, Jason Kihyuk
    Smith, Steven G.
    Mallett, Stephen
    Albers, Frank C.
    Bradford, Eric S.
    Yancey, Steven W.
    Liu, Mark C.
    RESPIRATORY RESEARCH, 2021, 22 (01)
  • [30] Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON
    Peck-Radosavljevic, M.
    Lencioni, R.
    Ozgurdal, K.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S124 - S125
12345